

BSE SENSEX 77,210 S&P CNX 23,501



Bloomberg	STARHEAL IN
Equity Shares (m)	585
M.Cap.(INRb)/(USDb)	303.9 / 3.6
52-Week Range (INR)	675 / 455
1, 6, 12 Rel. Per (%)	-9/-9/-30
12M Avg Val (INR M)	547

#### Financials Snapshot (INR b)


Y/E March	2024	2025E	2026E
NEP	129.4	151.7	181.5
U/W Profit	0.9	3.1	5.2
PBT	11.3	15.0	18.9
PAT	8.5	11.2	14.2
<b>Ratios (%)</b>			
Claims	66.5	65.3	65.3
Commission	13.2	13.0	13.0
Expense	17.0	16.4	15.6
Combined	96.7	94.7	93.9
RoE	12.8	15.6	16.8
EPS (INR)	14.4	19.2	24.2
EPS growth (%)	35.8	33.1	26.1
<b>Valuations</b>			
P/E (x)	35.9	27.0	21.4
P/BV (x)	4.6	3.9	3.3

#### Shareholding pattern (%)

As On	Mar-24	Dec-23	Mar-23
Promoter	57.9	57.9	58.3
DII	11.1	6.1	1.4
FII	26.6	31.0	35.2
Others	4.4	5.0	5.0

FII Includes depository receipts

#### Stock Performance (1-year)



CMP: INR519

TP: INR730 (+41%)

Buy

#### Robust growth outlook, attractive valuations

- Star Health's stock performance has been under pressure due to concerns over business model sustainability for standalone health insurers (SAHIs) if the government modifies the Insurance Act to allow a composite license.
- We note that SAHIs have inherent business model strengths that are difficult to replicate in a short time, such as a wide product portfolio, deep engagement with hospitals, claims processing capabilities and underwriting capabilities.
- On the other hand, life insurers have built an agency network over the years that gives them an advantage. Nevertheless, there is an overlap of life insurance agents having tie-ups with health insurers and changing the same would not be easy.
- In line with its guidance, Star Health delivered 18-20% premium growth in Apr-May'24. In the medium term, we expect combined ratio improvement to be driven by an increase in the share of its bancassurance channel (mainly credit-linked benefits-based products) and unwinding of URR from 1) the price hike of FHO implemented in FY24 and 2) a rising share of long-term products.
- We expect Star Health to report a CAGR of 18%/29% in NEP/PAT over FY24-26E and RoE to improve to 17% in FY26 from 13% in FY24. The stock trades at FY26E P/E of 21x. We maintain BUY with a one-year TP of INR730.

#### Composite license: Inherent business model bodes well for SAHIs

Recently, Mr. Siddhartha Mohanty, Chairman of Life Insurance Corp. of India (LIC), made an announcement that the insurer may enter the health insurance segment and can explore inorganic options if a composite license is approved by the government. This move would need a change in the Insurance Act. After this announcement, concerns have been raised around the sustainability of the leadership of SAHIs. The key concern is that life insurers will disrupt the business model and SAHIs could lose market share.

With the entry of new players, the market share loss is inevitable, but we note that SAHIs' inherent business model still gives them an advantage:

- Claims processing capabilities:** In FY23, the industry processed 27.5m health insurance claims vs. 2.3m life insurance claims. The frequency of claims in health insurance and the complexity of claims processing is multi-fold of life insurance claims. SAHIs have built robust processes, which have evolved over the years using the historical claims experience. This is difficult to replicate.
- Hospital network:** SAHIs have developed deep relationships and engagement with hospital networks in the country and have set up network agreements, which offer a win-win deal to all stakeholders (customer, insurer and hospital). Star Health/CARE/Niva Bupa/Manipal Cigna have arrangements with 14,295/9,400+/10,000+/8,500+ hospitals.

Research Analyst: Prayesh Jain (Prayesh.Jain@MotilalOswal.com) | Nitin Aggarwal (Nitin.Aggarwal@MotilalOswal.com)

Research Analyst: Nemin Doshi (Nemin.Doshi@MotilalOswal.com) | Muskan Chopra (Muskan.Chopra@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

- **Product innovation:** SAHIs, through their robust database on medical history of Indian population, have been launching specialized products, such as cancer care, diabetes care, senior citizen, young star and women specific. Emulating the same in the initial stages would be a challenge for life insurers.

#### Agency strength of life insurers a key distribution advantage

- Life insurance companies have been increasing their agency count over the past few years. The total count for the industry/private players/LIC has gone up by 27%/38%/17% between FY20 and FY24. In FY24, the industry increased the agency count by 10.6%.
- We note that the agency channel dominates retail health distribution with a 73% share for the industry in FY23.
- A majority of the agents selling health insurance products are associated with life insurance companies. In case a composite license is allowed, shifting the customer base from the existing health insurance company to another player will be a tall task.

#### Product mix likely to be favorable

- Star Health is focusing on improving its product mix, wherein the share of credit-linked benefits based products sold via the bancassurance channel is expected to double over the next few years from 5% in FY24.
- Additionally, the share of long-term policies (greater than one-year term) has increased to 6%. As URR unwinds into NEP from these businesses, we expect improvements in the combined ratio.
- Similarly, the price hike implemented for renewal policies of Family Health Optima benefitted GWP in FY24, but will be earned as NEP in FY25, which will help the combined ratio.

#### Expanding branch and hospital network

- Star Health has the deepest branch presence in the country among SAHIs and private players. This bodes well for a granular growth over the medium term.
- Of over 19,000 pin codes in India, the company is present in 17,106 pin codes via its sales distribution network.
- Even in terms of hospital network, it has been expanding its presence and deepening its association.
- The ratio of hospitals with agreements to total hospitals increased from 65% in FY21 to 74% in FY23. Resultantly, the share of cashless claims being processed at these hospitals increased from 55% in FY21 to 74% in FY24.

#### Loss ratios to improve in FY25

- About 87% of paid claims in FY24 were cashless vs. 80% in FY23. Cashless TAT improved with 95% of claims being settled within two hours.
- Around 34% of agreed network hospitals (representing 75% of the cashless claims) have been on-boarded under the authorized auto adjudication initiative. This helps to drastically reduce TAT.
- Star Health has also tightened its underwriting standards to enhance its focus on quality business, leading to recalibration of some geographies and portability business.

- Furthermore, benefits of price hikes, mix shifting toward benefit-based products and further gains from fraud detection will help reduce the overall loss ratio.


### Valuation and view: Focusing on profitable growth; reiterate BUY

- Star Health has tightened its underwriting standards to focus on high-quality business. We remain optimistic about the overall prospects for Star Health, backed by: a) strong growth in retail health, given under-penetration, b) strong push from the banca channel, c) sustained growth in specialized products, and d) deepening presence.
- Star Health is expected to increase prices by 15-20% in 1QFY25 for its senior citizen health insurance product and Young Star insurance product. These products account for ~10% of the total premium.
- We believe that Star Health can deliver long-term growth with the investments made in profitable channels and products. We reiterate our BUY rating on the stock with a TP of INR730 (based on 30x FY26E EPS).

### Exhibit 1: Sizing up the retail health potential 5-8x by FY30


	FY23	FY30	Remarks
No of customers (m)	53	37	Assuming 5% drop in count every year
Ticket size (INR)	6,573	12,809	Assuming 10% CAGR due to premium hikes, SA increase
Industry gross premium (INR b)	348	473	
Ratio of new customers to existing customers until FY30 (x)	1.0	1.5	2.0
New customers (m)	53	79	106
20% lower ticket size (INR)	10,247	10,247	10,247
FY30 Industry size of new customers (INR b)	542	813	1,084
FY30 total customer base (m)	90	116	143
Total Industry in FY30 (INR b)	1,015	1,286	1,557
FY23-30 CAGR (%)	17	21	24
Total industry size in FY30 vs FY23	2.9	3.7	4.5
			5.3
			6.0
			6.8
			7.6

### Exhibit 2: Retail health industry growth picking up pace after Covid




Source: IRDAI, MOFSL, Company


### Exhibit 3: GWP growth for STARHEALTH




Source: IRDAI, MOFSL, Company

**Exhibit 4: SAHIs gaining market share in retail health (%)**


Source: MOFSL, Company

**Exhibit 5: Star Health's market share inching upward (%)**


Source: MOFSL, Company

**Exhibit 6: Claims ratio expected to settle at around ~65.3%**


Source: MOFSL, Company

**Exhibit 7: Combined ratio to moderate in coming years**


Source: MOFSL, Company

**Exhibit 8: Trend in PAT**


Source: MOFSL, Company

**Exhibit 9: ROE to trend upward**

Source: MOFSL, Company

**Exhibit 10: Total number of agents across segments**


Source: MOFSL, GIC Council, IRDAI

**Exhibit 11: Number of claims registered by health and life insurance players in FY23 (m)**


Source: MOFSL, GIC Council, IRDAI

**Exhibit 12: Total number of agents added by Life insurance players in FY24 (In m)**


Insurer	No. of Agents as of 01-Apr-2023	ADDITION in FY24	DELETION in FY24	Net No. of Agents in FY24	YoY growth (%)
Private Insurers	1.3	0.6	0.3	1.5	38
LIC	1.3	0.5	0.4	1.4	17
Total	2.6	1.0	0.7	2.9	27

**Exhibit 13: Retail premium mix for specialized products for Star Health (%)**

Source: MOFSL, Company

**Exhibit 14: Trend in GWP mix (%)**

Source: MOFSL, Company

**Exhibit 15: One-year forward P/E chart**

Source: MOFSL, Company

## Financials and valuations

Income Statement								(INR m)
Y/E March	2019	2020	2021	2022	2023	2024	2025E	2026E
Retail Health	46,789	58,252	82,075	1,00,870	1,19,475	1,39,512	1,67,414	2,00,897
Group Health	5,938	8,897	9,963	12,066	8,076	10,824	12,989	14,937
PA	1,270	1,337	1,489	1,685	1,939	2,117	2,435	2,800
<b>Total GDPI</b>	<b>54,013</b>	<b>68,651</b>	<b>93,885</b>	<b>1,14,635</b>	<b>1,29,525</b>	<b>1,52,545</b>	<b>1,82,838</b>	<b>2,18,635</b>
Change (%)	29.8	27.1	36.8	22.1	13.0	17.8	19.9	19.6
NWP	41,287	52,395	71,794	1,08,096	1,23,196	1,40,674	1,68,610	2,01,621
<b>NEP</b>	<b>36,624</b>	<b>46,841</b>	<b>46,266</b>	<b>98,092</b>	<b>1,12,616</b>	<b>1,29,383</b>	<b>1,51,749</b>	<b>1,81,459</b>
Change (%)	33.7	27.9	-1.2	112.0	14.8	14.9	17.3	19.6
Net claims	22,976	30,874	43,695	85,400	73,204	85,999	99,064	1,18,459
Net commission	2,637	3,404	14,922	16,828	16,828	18,537	21,960	26,259
Expenses	9,827	11,013	14,031	18,443	20,538	23,944	27,667	31,514
Employee expenses	7,220	8,526	11,765	13,436	14,537	16,122	18,056	20,223
Other expenses	2,607	2,487	2,266	5,007	6,001	7,823	9,611	11,291
<b>Underwriting Profit/(Loss)</b>	<b>1,184</b>	<b>1,550</b>	<b>-17,316</b>	<b>-20,673</b>	<b>2,046</b>	<b>903</b>	<b>3,058</b>	<b>5,227</b>
Investment income (PH)	1,398	1,639	2,505	4,796	5,014	6,407	7,338	8,455
Operating profit	2,477	3,303	-14,811	-15,877	7,060	7,309	10,396	13,682
Investment income (SH)	612	1,212	1,718	3,214	3,287	4,089	5,128	5,822
<b>PBT</b>	<b>2,652</b>	<b>4,062</b>	<b>-14,458</b>	<b>-14,024</b>	<b>8,264</b>	<b>11,289</b>	<b>14,998</b>	<b>18,913</b>
Tax	540	1,389	-3,601	-3,559	2,078	2,838	3,749	4,728
Tax rate (%)	20.4	34.2	24.9	25.4	25.1	25.1	25.0	25.0
<b>PAT</b>	<b>2,112</b>	<b>2,633</b>	<b>-10,857</b>	<b>-10,464</b>	<b>6,186</b>	<b>8,450</b>	<b>11,248</b>	<b>14,185</b>

Balance sheet								(INR m)
Y/E March	2019	2020	2021	2022	2023	2024	2025E	2026E
Equity Share Capital	4,556	4,906	5,481	5,755	5,817	5,853	5,853	5,853
Reserves & Surplus	7,726	14,132	29,516	40,285	59,839	60,429	71,678	85,863
<b>Net Worth</b>	<b>12,282</b>	<b>19,038</b>	<b>34,996</b>	<b>46,040</b>	<b>65,656</b>	<b>66,282</b>	<b>77,530</b>	<b>91,715</b>
FV change	-	31	-76	267	234	1,036	1,139	1,253
Borrowings	2,500	2,500	2,500	7,200	4,700	4,700	4,700	4,700
Other liabilities	33,943	38,361	67,589	81,629	92,988	1,08,525	1,29,862	1,55,752
<b>Total Liabilities</b>	<b>48,725</b>	<b>59,930</b>	<b>1,05,010</b>	<b>1,35,136</b>	<b>1,63,577</b>	<b>1,80,543</b>	<b>2,13,232</b>	<b>2,53,420</b>
Investments (SH)	9,523	18,110	27,941	44,939	53,459	63,361	73,264	83,166
Investments (PH)	20,778	24,789	40,426	68,796	80,462	91,548	1,04,850	1,20,813
Net Fixed Assets	981	1,019	990	1,171	1,113	1,751	1,801	1,851
Def Tax Assets	1,420	70	4,213	7,767	5,689	3,582	3,582	3,582
Current Assets	7,093	9,827	12,650	6,828	8,444	12,990	15,569	18,617
Cash & Bank	8,930	6,114	18,790	5,635	14,410	7,312	14,166	25,391
<b>Total Assets</b>	<b>48,725</b>	<b>59,930</b>	<b>1,05,010</b>	<b>1,35,136</b>	<b>1,63,577</b>	<b>1,80,543</b>	<b>2,13,232</b>	<b>2,53,420</b>

E: MOFSL Estimates

## Financials and valuations

### Ratios

Y/E March	2019	2020	2021	2022	2023	2024	2025E	2026E
GWP growth	29.8	27.1	36.8	22.1	13.0	17.8	19.9	19.6
NWP growth	29.2	26.9	37.0	50.6	14.0	14.2	19.9	19.6
<b>NEP growth</b>	<b>33.7</b>	<b>27.9</b>	<b>-1.2</b>	<b>112.0</b>	<b>14.8</b>	<b>14.9</b>	<b>17.3</b>	<b>19.6</b>
Claim ratio	62.7	65.9	94.4	87.1	65.0	66.5	65.3	65.3
Commission ratio	6.4	6.5	20.8	15.6	13.7	13.2	13.0	13.0
Expense ratio	23.8	21.0	19.5	17.1	16.7	17.0	16.4	15.6
<b>Combined ratio</b>	<b>92.9</b>	<b>93.4</b>	<b>134.8</b>	<b>119.7</b>	<b>95.3</b>	<b>96.7</b>	<b>94.7</b>	<b>93.9</b>
<b>Profitability Ratios (%)</b>								
RoE	19.3	16.8	-40.2	-25.8	11.1	12.8	15.6	16.8

Valuations	2019	2020	2021	2022	2023	2024	2025E	2025E
BVPS (INR)	27.0	38.8	63.9	80.0	112.9	113.2	132.5	156.7
Change (%)	28.0	43.9	64.6	25.3	41.1	0.3	17.0	18.3
<b>Price-BV (x)</b>	<b>19.2</b>	<b>13.3</b>	<b>8.1</b>	<b>6.5</b>	<b>4.6</b>	<b>4.6</b>	<b>3.9</b>	<b>3.3</b>
EPS (INR)	4.6	5.4	-19.8	-18.2	10.6	14.4	19.2	24.2
Change (%)	24.1	15.8	-469.1	-8.2	-158.5	35.8	33.1	26.1
<b>Price-Earnings (x)</b>					<b>48.7</b>	<b>35.9</b>	<b>27.0</b>	<b>21.4</b>

E: MOFSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal Capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal Capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

#### Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

**Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

**Terms & Conditions:**

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no warranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

**Disclaimer:**

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; [www.motilaloswal.com](http://www.motilaloswal.com).

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: [na@motilaloswal.com](mailto:na@motilaloswal.com), Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	<a href="mailto:query@motilaloswal.com">query@motilaloswal.com</a>
Ms. Kumud Upadhyay	022 40548082	<a href="mailto:servicehead@motilaloswal.com">servicehead@motilaloswal.com</a>
Mr. Ajay Menon	022 40548083	<a href="mailto:am@motilaloswal.com">am@motilaloswal.com</a>

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI:

ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to [query@motilaloswal.com](mailto:query@motilaloswal.com). In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com), for DP to [dpgrievances@motilaloswal.com](mailto:dpgrievances@motilaloswal.com).